Revolution Medicines (RVMD) Free Cash Flow (2019 - 2026)

Revolution Medicines' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$355.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 79.98% year-over-year to -$355.0 million in Q1 2026; TTM through Mar 2026 was -$1.1 billion, a 79.84% decrease from a year earlier, with the FY2025 full-year figure at -$913.7 million, down 63.45% from the prior year.
• Free Cash Flow retreated to -$355.0 million in Q1 2026 per RVMD's latest filing, from -$277.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$51.6 million in Q3 2022 and bottomed at -$355.0 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$130.8 million (2024), against an average of -$141.6 million.
• Biggest YoY gain for Free Cash Flow was 11.05% in 2024; the steepest drop was 154.11% in 2024.
• Year by year, Free Cash Flow stood at -$61.3 million in 2022, then plunged by 92.17% to -$117.8 million in 2023, then decreased by 11.05% to -$130.8 million in 2024, then plunged by 112.2% to -$277.5 million in 2025, then fell by 27.91% to -$355.0 million in 2026.
• Per Business Quant, the three latest RVMD Free Cash Flow figures stand at -$355.0 million (Q1 2026), -$277.5 million (Q4 2025), and -$209.3 million (Q3 2025).